Creative Biolabs Launches End-to-End AI-Driven Antibody Solutions to Accelerate Biotherapeutic Discovery and Engineering

Creative Biolabs has launched an end-to-end AI-driven antibody solutions platform aimed at accelerating biopharmaceutical discovery and engineering

The platform integrates generative AI models, structural biology tools (such as IgFold, ABodyBuilder2, and DeepAb), and high-throughput experimental workflows to compress early-stage discovery and optimization timelines from years to under two months

Core capabilities include de novo antibody sequence generation, AI-driven antibody engineering, humanization, developability optimization, and bispecific antibody design, with an emphasis on balancing affinity, stability, and low immunogenicity

The service leverages an AI–wet lab closed-loop system (AbForge® platform) where computational design is continuously refined using experimental data, enabling rapid iteration and validation of lead candidates